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Background and Objectives. Leukemia relapse
occurring in donor cells after allogeneic hematopoi-
etic stem cell transplantation has been reported in
rare cases. Cytogenetic analysis and molecular
probing of variable number of tandem repeats
(VNTRs) have been used to confirm this unusual
event in the few cases so far reported in the litera-
ture. The aim of this study was to demonstrate that
extensive molecular characterization of leukemic
cells at diagnosis and relapse may be necessary to
avoid many technical pitfalls possibly leading to an
erroneous diagnosis of leukemia relapse in donor
cells after allogeneic transplantation.
Design and Methods. We report the case of a 49-
year old man who received an allogeneic transplan-
tation from his HLA-identical sister because of BCR-
ABL+ acute lymphoblastic leukemia (ALL). After hav-
ing achieved complete hematologic and molecular
remission, two years later an overt leukemia relapse
occurred with cytogenetic findings suggesting a
leukemia relapse in donor cells. The donor or patient
origin of leukemic cells at relapse was further inves-
tigated by fluorescence in situ hybridization (FISH)
karyotyping, reverse transcription (RT) polymerase
chain reaction (PCR) analysis of BCR-ABL chimeric
transcripts, PCR amplification of several VNTRs and
the Y chromosome-specific DYS14 sequence and
finally by amplification, cloning and sequencing of
the CDRIII region of the immunoglobulin heavy chain
(IgH) gene.
Results. At the time of relapse, conventional and
FISH karyotyping revealed the presence of a Phl+
chromosome and a female karyotype in all the 25
metaphases analyzed and PCR amplification of the
Y chromosome-specific DYS14 sequence was neg-
ative. Moreover, the molecular evaluation of hema-
topoietic chimerism performed by the NZ-22 VNTR
allowed us to demonstrate that at the time of
relapse, a consistent proportion of hematopoietic
cells was of donor origin. However, the molecular
cloning and sequencing of the CDRIII region of the
immunoglobuin heavy chain (IgH) gene rearrange-
ment in leukemic blasts at diagnosis and relapse
demonstrated their identity thus formally proving the
patient origin of both leukemic clones.
Interpretation and Conclusions. While the simplest
interpretation of the apparent female karyotype at
relapse is the consequence of a loss of the Y chro-
mosome which in leukemic blasts took place along
with duplication of an X-chromosome, this case
strongly emphasizes the need for accurate and
extensive molecular characterization to prove the
donor origin of a leukemia relapse after allogeneic
transplantation.
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Key words: alloBMT, donor cell leukemia, IgH gene rearrange-
ment
ABSTRACT
Need for an accurate molecular diagnosis to assess the donor origin
of leukemia relapse after allogeneic stem cell transplantation
ORIETTA SPINELLI, URSULA GIUSSANI, GIANMARIA BORLERI, MANUELA LAZZARI, ANNA MICHELATO, GIANPIETRO DOTTI, 
TIZIANO BARBUI, ALESSANDRO RAMBALDI
Divisione di Ematologia e Centro Trasfusionale, Ospedali Riuniti di Bergamo, Italy
Correspondence: Alessandro Rambaldi, M.D., Division of Hematology,
Ospedali Riuniti di Bergamo, largo Barozzi 1, 24100 Bergamo, Italy.
Phone: international +39-035-269491 – Fax:international +39-035-
269667 – E-mail: ematologia@cyberg.it.
The occurrence of leukemic transformationof donor cells in vivo after allogeneic trans-plantation has been reported in several cas-
es.1 To date the pathogenic mechanisms, which
most likely take place in the donor after engraft-
ment, still remain to be elucidated and different
hypotheses have been proposed. Possible envi-
ronmental factors, transfer of oncogenic mater-
ial from host to donor2 and viral infections, such
as that caused by Epstein-Barr virus (EBV),3 have
all been suggested to play a crucial role in gen-
erating the new transformation event. Interest-
ingly, recent data have provided new evidence for
a direct link between viral genes and specific
chromosome translocations such as in the case
of adenovirus E1A for EWS-FLI1 fusion transcript
characteristic of Ewing’s tumor.4 However, at
least in some cases the donor origin of the
leukemia relapse could be misinterpreted
because of the lack of adequate molecular analy-
sis. The case we describe here underlines this pos-
sibility and strongly suggests that appropriate
experiments and controls should be performed
before such a diagnosis is made.
Design and Methods
Patient and donor samples
Peripheral blood or bone marrow samples
were taken from the patient and the donor after
informed consent, using forms approved by the
Institutional Review Board, had been obtained.
Immunophenotyping
The immunophenotyping was performed by
flow cytometry on freshly isolated leukemic cells
using the following fluorescein isothiocyanate
(FITC)-conjugated or phycoerythrin (PE)-conju-
gated monoclonal antibodies: anti-CD45,
CD13, CD33, CD3, CD5, CD7, CD19, CD20,
CD10, CD34, HLA-DR, CD11b and FACScan
analyzer (Becton Dickinson, San José, CA, USA).
Karyotyping
Conventional karyotyping of leukemic blasts
was performed according to standard methods
of G-banded chromosome preparations on
freshly isolated cells and after in vitro incubation
for 48 hours with and without mitogens. Fluo-
rescence in situ hybridization (FISH) was per-
formed using commercially available BCR-ABL
double color labeled probes (Oncor, Gaithers-
burg, MD, USA).
Molecular findings
Total cellular RNA and high molecular weight
DNA were extracted according to standard meth-
ods.5 Reverse transcription-polymerase chain
reaction (RT-PCR) of the BCR-ABL chimeric tran-
script and amplification of variable number of
tandem repeat (VNTR) loci including ApoB,
ApoC2, YNZ-22, MCT118, 33.6, D11S533 or the
Y chromosome specific DYS14 sequence were
performed using a Thermal Cycler 9600 appara-
tus (Perkin Elmer Cetus, Norwalk, CT, USA) as
described elsewhere.5,6 PCR amplification,
cloning and sequencing of the CDRIII region of




In October 1996 a 49-year old man was
admitted to our Department with a diagnosis
of acute lymphoblastic leukemia (ALL). His
hemoglobin concentration was 10.7 g/dL, white
cell count 8×109/L, platelet count 25×109/L and
his bone marrow was packed with lymphoblasts
showing an immunophenotype consistent with
a diagnosis of B-precursor ALL (CD19+, CD10+,
CD20+, CD34+, HLA-DR+, CD33-, CD11b-).
While conventional cytogenetic analysis showed
a normal karyotype, the molecular RT-PCR
analysis of t(9;22) chromosome translocation
documented a BCR-ABL gene rearrangement
(e1a2 breakpoint) coding for the p190 chimeric
oncoprotein. The patient was treated according
to the institutional protocol and enrolled into an
allogeneic stem cell transplantation program. In
January 1997, after a conditioning regimen
based on busulfan (16 mg/kg) and melphalan
(110 mg/m2) he received granulocyte colony-
stimulating factor (G-CSF)-mobilized peripher-
al blood stem cells (5×106 CD34+ cells/kg) col-
lected from an HLA-identical female sibling
donor. Cyclosporin A (CyA) and methotrexate
were given for graft-versus-host disease (GVHD)
prophylaxis. With this treatment, the patient
achieved a complete hematologic and molecu-
lar remission as documented by repeated nega-
tive results of nested RT-PCR analysis of the
BCR-ABL gene. Twenty-four months after trans-
plantation, because of fever, myalgia and low
back pain, bone marrow was aspirated and
despite the lack of morphologically identifiable
leukemic blasts, RT-PCR analysis documented
the reappearance of the BCR-ABL (e1a2)
chimeric transcript. Two months later a bone
marrow aspirate revealed an overt leukemia
relapse (more than 50% leukemic blasts) with
an immunophenotype similar but not identical
to that documented at diagnosis (CD19+,
CD10+, CD20–, CD34+, HLA-DR+, CD33+,
CD11b+). Conventional cytogenetic analysis 47,
XX, del(9) (p21), +i(17) (q10), del(20) [47,
(q12), ider(22) (qter), t(9;22) (q34;q11)]
revealed the presence of multiple karyotypic
abnormalities including the Ph1+ chromosome
and surprisingly, an apparent female karyotype
in all the 25 metaphases analyzed (Figure 1,
panel A). FISH analysis and RT-PCR confirmed
the presence of the Ph1+ chromosome and that
of a BCR-ABL (e1a2) chimeric gene (Figure 1,
Panel B and Figure 2, panel A). The patient did
not respond to a further chemotherapy program
and died soon after.
Molecular evaluation of the origin of the
leukemic relapse
The discrepancy between a normal karyotype
at diagnosis and the presence of a Ph1+ chro-
mosome at relapse could reflect the well known
inability of cytogenetic analysis to detect the
neoplastic clone in some cases of ALL. Most
striking however, was the presence of an appar-
ently female karyotype in leukemic blasts isolat-
ed at the moment of relapse which prompted
us to confirm at the molecular level the donor
origin of the leukemia relapse. Although PCR
analysis had revealed the same BCR-ABL (e1a2)
chimeric transcript in leukemic blasts at diag-
nosis and relapse, the huge length (> 55 Kb) of
the minor breakpoint cluster  region (m-bcr) did
not allow us to perform a simple Southern blot
analysis to investigate the DNA breakpoints of
the BCR gene on chromosome 22.7 Therefore
we performed PCR amplification of the Y chro-
mosome-specific DYS14 sequence in DNA sam-
ples isolated at diagnosis and relapse. As shown
in Figure 2, panel B, while the male origin of the
leukemic clone at diagnosis was evident, no
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amplification of the DYS14 sequence occurred
at relapse. To identify other, more informative
probes, the molecular analysis of several VNTRs
including Apo B, Apo C2, MCT118, and 33.6,
D11S533 was performed but none of these dis-
criminated between patient and donor cells
(data not shown). The analysis performed with
the YNZ-22 probe, while suggesting that at the
time of relapse a relevant proportion of
hematopoietic cells were of donor origin, could
not formally rule out the presence of patient’s
leukemic cells because of co-migration of two
alleles (Figure 2, panel C). Therefore a further set
of experiments was performed in order to iden-
tify an unequivocal marker of clonality. We then
decided to clone and sequence the IgH gene
rearrangements detected in leukemic blasts iso-
lated at diagnosis and relapse. This set of exper-
iments was performed by PCR amplification,
cloning and sequencing of the CDRIII region of
the IgH gene rearrangements.5 As shown in Fig-
ure 3, the DNA sequencing demonstrated the
identity of the two CDRIII regions thus formally
proving the patient origin of the leukemia
relapse.
Discussion
Here we report a leukemia relapse, occurring in
a man after allogeneic transplantation from an
HLA-identical sister, in which cytogenetic analy-
sis strongly suggested the donor origin of the
leukemic cells. This diagnosis was further sug-
gested by the PCR results obtained using a sen-
sitive Y-chromosome specific molecular probe
and by the molecular analysis performed with
the YNZ-22 VNTR.6 However, the possibility of
generating a leukemia-specific probe based on
the unique DNA rearrangement of the IgH gene
allowed unequivocal demonstration of the
patient origin of the leukemic relapse. Because
many additional, secondary genetic defects can
occur after a myeloablative conditioning regi-
men, the simplest interpretation of the apparent
female karyotype at relapse is the consequence of
Figure 1. Karyotypic analysis at relapse. Conventional cyto-
genetic analysis of the leukemic blasts at relapse indicates
an apparently female karyotype (panel A) and the presence
of a Ph1+ chromosome (arrow). Fluorescence in situ
hybridization using differently colored BCR and ABL probes
allowed the detection of the Ph1+ chromosome (red, yellow
and green spots), the abnormal chromosome 9 (red/green
spots), the normal chromosome 22 (red spot) and 9 (green
spot) (panel B).
Figure 2. Molecular evaluation of donor and host origin of
leukemic cells. Molecular analysis on RNA or DNA obtained
from donor hematopoietic stem cells (lane 1), leukemic
blasts at diagnosis (lane 2), patient’s bone marrow at day
+365 after transplantation (lane 3) and patient’s bone mar-
row at relapse (lane 4). Panel A summarizes the RT-PCR
analysis of the BCR-ABL chimeric transcript (e1a2 break-
point) with the amplification of the normal ABL gene used
as RNA quality control. Panel B and C report the PCR ampli-
fication of a Y-chromosome sequence (DYS14) and a chro-
mosome 17 derived VNTR (YNZ-22). Amplification of the
coagulation factor V gene was used as a control of the DNA
quality.
the loss of the Y chromosome which could have
eventually taken place along with duplication of
an X-chromosome. Leukemia transformation of
engrafted human bone marrow cells was first
described more than thirty years ago8 when the
lack of adequate molecular tools at that time cut
down the chances of making a precise molecu-
lar diagnosis of the leukemic clone. Therefore, in
the majority of cases, conventional cytogenetics
has been used to confirm the donor origin of the
leukemic relapse and several technical pitfalls
may have been encountered. More recently,
sophisticated, FISH-based cytogenetic tech-
niques have also been employed but usually they
have been equally applied to investigate sex-relat-
ed chromosomes.1 Interestingly, the use of mol-
ecular probes for the evaluation of highly poly-
morphic DNA sequences (VNTRs) and restric-
tion fragment length polymorphisms (RFLPs) in
some cases corroborated, with more robust evi-
dence, the diagnosis of leukemia recurrence in
donor cells.2 In other cases, however, this mole-
cular analysis allowed correction of the erro-
neous assignment of a donor origin to a sec-
ondary leukemia thus confirming the inadequa-
cy of a diagnosis based only on sex-related cyto-
genetic markers.9 However, in some cases, it was
shown that even the molecular analysis of VNTR
could not definitively assign the origin of the
leukemic clone because deletion or amplification
of chromosomal segments carrying marker loci
may lead to a misinterpretation of results.10,11
Overall, only a few cases of those so far report-
ed in the literature could provide an unequivocal
and leukemia-specific molecular marker demon-
strating the donor origin of the leukemia relapse
after allogeneic transplantation. Our results
strongly emphasize the need to identify leukemia-
specific sequences, which may represent the only
definitive tool to identify the origin of a malig-
nant clone during its natural history in a patient
despite possible further genetic evolution.
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Potential implications for clinical practice
♦ Our results indicate that a diagnosis of leukemia
relapse in donor cells can not be supported only
by cytogenetic evidence and must be demon-
strated by an accurate molecular characteriza-
tion of the leukemic cells using unequivocal,
clone specific molecular probes. In the absence of
such a characterization, the diagnosis of
leukemia relapse in donor cells should not be
accepted.
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